View Older Stories View More Recent Stories

Aug 21, 2025 08:22AM Gilead stock falls after CVS holds off adding HIV prevention shot to plans
Aug 21, 2025 08:06AM BMO Capital on Gilead Sciences (GILD): 'Expect GILD shares to be weaker on this announcement'
Aug 7, 2025 04:25PM Gilead posts flat second quarter profit, ups full-year outlook on strong HIV sales
Jun 30, 2025 07:31AM Gilead extends gains after Supreme Court upheld an Obamacare provision
Jun 18, 2025 03:21PM Gilead Sciences (GILD) Yeztugo approval a 'major win' - BMO Capital
Jun 10, 2025 10:01AM US FDA pauses Gilead trials testing experimental HIV pill combination
Apr 9, 2025 09:19AM Pharma stocks slide after Trump signals tariffs on sector
Mar 19, 2025 10:05AM BMO Capital Reiterates Outperform on Gilead Sciences (GILD) Amid 'Potential HHS HIV Funding Cuts'
Feb 12, 2025 10:30AM Gilead Sciences (GILD) PT Raised to $115 at BMO Capital; 'More Growth Coming in 25'
Nov 5, 2024 02:21PM BMO Capital Reiterates Outperform Rating on Gilead Sciences (GILD)
Oct 21, 2024 07:55AM BMO Capital Reiterates Outperform Rating on Gilead Sciences (GILD)
Sep 12, 2024 09:55AM BMO Capital Gilead Sciences (GILD) at Outperform following latest HIV data
Aug 15, 2024 08:56AM BMO Capital Reiterates Outperform Rating on Gilead Sciences (GILD)
Aug 9, 2024 07:16AM Gilead Sciences (GILD) PT Raised to $85 at BMO Capital
Jun 20, 2024 12:28PM BMO Capital on Gilead Sciences (GILD): 'If positive, PURPOSE-2 could allow for an approval of lenacapavir as early as late 2025'
Jun 3, 2024 08:59AM BMO Capital Reiterates Outperform Rating on Gilead Sciences (GILD)
May 23, 2024 07:36AM BMO Capital Reiterates Outperform Rating on Gilead Sciences (GILD)
May 20, 2024 05:22AM BMO Capital Reiterates Outperform Rating on Gilead Sciences (GILD)
Mar 15, 2024 10:25AM BMO Capital Reiterates Outperform Rating on Gilead Sciences (GILD)
Feb 12, 2024 08:42AM Gilead to buy CymaBay for $4.3 billion in bets on liver disease treatment
May 16, 2023 09:22AM Gilead Sciences (GILD) cell therapy unit can grow to multi-billion dollar business by end of 2023 - BMO Capital
May 16, 2023 04:16AM BMO Capital Upgrades Gilead Sciences (GILD) to Outperform, 'Best-in-Class Cell Tx Biz'
Aug 3, 2022 05:55AM "Yet to See True Next Leg of Growth" - BMO Capital Keeps Gilead Sciences (GILD) at Market Perform
Aug 2, 2022 04:31PM Gilead quarterly profit falls as COVID antiviral sales decrease
Jun 6, 2022 06:30AM BMO Capital Reiterates Market Perform Rating on Gilead Sciences (GILD)
Apr 28, 2022 05:13PM BMO Capital Reiterates Market Perform Rating, $64 Price Target on Gilead Sciences (GILD) Following Q1 Report, "Continue to See Gilead at a Crossroads"
Mar 7, 2022 09:58AM BMO Capital Reiterates Gilead Sciences (GILD) at Market Perform, Sees TROPiCS-02 Results As Not Clinically Meaningful
Feb 28, 2022 04:09AM UPDATE: BMO Capital Downgrades Gilead Sciences (GILD) to Market Perform
Feb 16, 2022 06:09AM BMO Capital Reiterates Outperform Rating on Gilead Sciences (GILD) Going into Virology Deep Dive Event
Feb 2, 2022 05:20AM BMO Capital Lowers PT on Gilead (GILD) to $75 Following Earnings, Reiterates Focus on TROPiCS-02 Data Readout
Feb 2, 2022 05:20AM BMO Capital Lowers PT on Gilead (GILD) to $75 Following Earnings, Reiterates Focus on TROPiCS-02 Data Readout
Jan 13, 2022 04:50PM Gilead (GILD) Reiterates Confidence on Hitting PFS Improvement in HR+/HER2- Trial - BMO Capital Markets
Nov 18, 2021 04:08PM UPDATE: BMO Capital Assumes Gilead Sciences (GILD), Upgrades to Outperform
Feb 5, 2021 06:50AM Gilead Sciences (GILD) PT Raised to $67 at BMO Capital
Jan 12, 2021 06:27AM Gilead Sciences (GILD) PT Raised to $65 at BMO Capital
Oct 29, 2020 06:59AM Gilead Sciences (GILD) PT Lowered to $64 at BMO Capital
Apr 20, 2020 04:46AM BMO Capital Downgrades Gilead Sciences (GILD) to Market Perform; Risk/Reward Unfavorable
Apr 13, 2020 06:10AM Gilead Sciences (GILD) Compassionate Use Remdesivir Data Is an Incremental Positive - BMO Capital
Jul 31, 2019 07:35AM Gilead Sciences (GILD) PT Raised to $82 at BMO Capital
Jul 15, 2019 07:16AM Gilead Sciences (GILD) PT Lowered to $76 at BMO Capital
Mar 14, 2019 04:11PM BMO Capital Starts Gilead Sciences (GILD) at Outperform
Feb 12, 2019 09:20AM Pre-Open Stock Movers 02/12: (CASM) (ELLI) (COTY) Higher; (BRS) (VRNS) (LABL) Lower (more...)
Feb 8, 2018 08:41AM Gilead Sciences (GILD) PT Raised to $88 at BMO Capital
Jul 27, 2017 07:00AM Gilead Sciences (GILD): Raising PT To $82 - BMO
May 3, 2017 09:17AM Gilead Sciences (GILD) PT Raised to $76 at BMO Capital Following 1Q
Feb 9, 2017 06:41AM Gild Sciences (GILD) PT Drops to $75 at BMO on Bad Guidance
Jan 12, 2017 06:26AM Gilead Sciences (GILD): Management Meeting Confirms Below Consensus Outlook - BMO
Jan 12, 2017 06:22AM BMO Capital On Gilead (GILD): We Expect HIV Sales To Benefit From Bictegravir Launch
Nov 9, 2016 12:03PM Complete Donald Trump Stock Impact Guide
Nov 2, 2016 07:17AM UPDATE: BMO Capital Maintains Gilead Sciences (GILD) at Market Perform (Correction)
View More Recent Stories View Older Stories